{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loading+Dose+Arm&page=15",
    "query": {
      "intervention": "Loading Dose Arm",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 376,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loading+Dose+Arm&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loading+Dose+Arm&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T21:23:25.217Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04958265",
      "title": "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atypical Hemolytic Uremic Syndrome"
      ],
      "interventions": [
        {
          "name": "Crovalimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "28 Days to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-11-17",
      "completion_date": "2029-05-19",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04958265"
    },
    {
      "nct_id": "NCT05345197",
      "title": "Emicizumab in Patients With Acquired Hemophilia A",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Hemophilia A"
      ],
      "interventions": [
        {
          "name": "emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2022-08-31",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 16,
      "location_summary": "San Diego, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05345197"
    },
    {
      "nct_id": "NCT05431088",
      "title": "A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Osivelotor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 389,
      "start_date": "2022-09-22",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 46,
      "location_summary": "Mobile, Alabama • Hartford, Connecticut • New Haven, Connecticut + 27 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05431088"
    },
    {
      "nct_id": "NCT00305682",
      "title": "Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 295,
      "start_date": "2005-06",
      "completion_date": "2019-12-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00305682"
    },
    {
      "nct_id": "NCT00374088",
      "title": "N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transposition of Great Vessels",
        "Congenital Heart Disease"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "3 Months",
        "sex": "ALL",
        "summary": "Up to 3 Months"
      },
      "enrollment_count": 21,
      "start_date": "2005-02",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2012-01-19",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00374088"
    },
    {
      "nct_id": "NCT06131021",
      "title": "Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Periodontitis",
        "Periodontal Diseases",
        "Periodontal Pocket"
      ],
      "interventions": [
        {
          "name": "Amoxicillin",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2024-04-25",
      "completion_date": "2026-04-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06131021"
    },
    {
      "nct_id": "NCT02326298",
      "title": "An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2014-12-16",
      "completion_date": "2018-10-24",
      "has_results": true,
      "last_update_posted_date": "2019-11-07",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 8,
      "location_summary": "San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326298"
    },
    {
      "nct_id": "NCT01570036",
      "title": "Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Herceptin",
          "type": "DRUG"
        },
        {
          "name": "NeuVax vaccine",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "George E. Peoples",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 275,
      "start_date": "2013-05-21",
      "completion_date": "2018-09-28",
      "has_results": true,
      "last_update_posted_date": "2020-12-02",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 29,
      "location_summary": "Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570036"
    },
    {
      "nct_id": "NCT02656472",
      "title": "A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pediatric Cardiac Surgery",
        "Complication of Extracorporeal Circulation"
      ],
      "interventions": [
        {
          "name": "Tranexamic acid",
          "type": "DRUG"
        },
        {
          "name": "Epsilon Aminocaproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2016-02",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 1,
      "location_summary": "Oak Lawn, Illinois",
      "locations": [
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02656472"
    },
    {
      "nct_id": "NCT06172127",
      "title": "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection",
          "type": "DRUG"
        },
        {
          "name": "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedSIR",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2024-07-22",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-10-29T21:23:25.217Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06172127"
    }
  ]
}